Compare NEULAND LABS with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NEULAND LABS vs GSK PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NEULAND LABS GSK PHARMA NEULAND LABS/
GSK PHARMA
 
P/E (TTM) x 23.9 62.3 38.3% View Chart
P/BV x 1.9 9.6 20.3% View Chart
Dividend Yield % 0.4 6.0 7.0%  

Financials

 NEULAND LABS   GSK PHARMA
EQUITY SHARE DATA
    NEULAND LABS
Mar-21
GSK PHARMA
Mar-22
NEULAND LABS/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs2,3501,917 122.6%   
Low Rs2601,400 18.6%   
Sales per share (Unadj.) Rs730.3193.5 377.4%  
Earnings per share (Unadj.) Rs62.822.5 279.6%  
Cash flow per share (Unadj.) Rs93.826.5 353.9%  
Dividends per share (Unadj.) Rs5.0090.00 5.6%  
Avg Dividend yield %0.45.4 7.1%  
Book value per share (Unadj.) Rs613.0157.2 390.0%  
Shares outstanding (eoy) m12.83169.41 7.6%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x1.88.6 20.9%   
Avg P/E ratio x20.873.8 28.1%  
P/CF ratio (eoy) x13.962.6 22.2%  
Price / Book Value ratio x2.110.6 20.2%  
Dividend payout %8.0400.4 2.0%   
Avg Mkt Cap Rs m16,746280,960 6.0%   
No. of employees `000NANA-   
Total wages/salary Rs m1,4976,102 24.5%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m9,36932,780 28.6%  
Other income Rs m161758 21.2%   
Total revenues Rs m9,53033,538 28.4%   
Gross profit Rs m1,4687,735 19.0%  
Depreciation Rs m397682 58.2%   
Interest Rs m17920 896.7%   
Profit before tax Rs m1,0537,790 13.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2473,983 6.2%   
Profit after tax Rs m8063,808 21.2%  
Gross profit margin %15.723.6 66.4%  
Effective tax rate %23.551.1 45.9%   
Net profit margin %8.611.6 74.1%  
BALANCE SHEET DATA
Current assets Rs m5,49637,080 14.8%   
Current liabilities Rs m3,68516,984 21.7%   
Net working cap to sales %19.361.3 31.5%  
Current ratio x1.52.2 68.3%  
Inventory Days Days2691 28.9%  
Debtors Days Days848229 371.2%  
Net fixed assets Rs m7,7528,121 95.5%   
Share capital Rs m1291,694 7.6%   
"Free" reserves Rs m7,73624,936 31.0%   
Net worth Rs m7,86526,630 29.5%   
Long term debt Rs m8810-   
Total assets Rs m13,24845,201 29.3%  
Interest coverage x6.9391.3 1.8%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.70.7 97.5%   
Return on assets %7.48.5 87.8%  
Return on equity %10.314.3 71.7%  
Return on capital %14.129.3 48.0%  
Exports to sales %77.80-   
Imports to sales %29.527.0 109.3%   
Exports (fob) Rs m7,292NA-   
Imports (cif) Rs m2,7658,853 31.2%   
Fx inflow Rs m7,292528 1,381.6%   
Fx outflow Rs m2,7658,853 31.2%   
Net fx Rs m4,527-8,325 -54.4%   
CASH FLOW
From Operations Rs m1,8948,107 23.4%  
From Investments Rs m-844-4,055 20.8%  
From Financial Activity Rs m-1,137-5,242 21.7%  
Net Cashflow Rs m-88-1,190 7.4%  

Share Holding

Indian Promoters % 36.2 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 23.6 12.9 182.7%  
FIIs % 17.2 2.2 788.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 63.8 25.0 255.1%  
Shareholders   32,257 110,141 29.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NEULAND LABS With:   SUN PHARMA    CIPLA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    



Today's Market

Sensex Ends 111 Points Lower, Nifty Holds 15,750; ONGC, Reliance Crash, while ITC & Bajaj Twins Gain 4%(Closing)

After opening the day deep in the red, Indian share markets slowly recovered most of their losses and ended on a flat note.

Related Views on News

GSK PHARMA 2021-22 Annual Report Analysis (Annual Result Update)

Jun 25, 2022

Here's an analysis of the annual report of GSK PHARMA for 2021-22. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

More Views on News

Most Popular

Best Monopoly Stocks to Own in 2022(Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

The One Smallcap Stock I'll Recommend Now(Profit Hunter)

Jun 21, 2022

This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.

Wait! Don't Buy the Smallcap 'Dip' Just Yet(Profit Hunter)

Jun 20, 2022

Why this may not be the best time to buy smallcaps.

5 Consistent Compounding Stocks Available at Discount. Time to Buy?(Views On News)

Jun 22, 2022

The good side of a market correction? Investors get consistent compounding stocks at a discount.

Looking for Value Stocks Amid Volatile Times? Consider These 5 Stocks(Views On News)

Jun 20, 2022

These value stocks have the potential to deliver good returns in the long run. Watch out for them.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NEULAND LABS SHARE PRICE


Jul 1, 2022 (Close)

TRACK NEULAND LABS

  • Track your investment in NEULAND LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NEULAND LABS 5-YR ANALYSIS

COMPARE NEULAND LABS WITH

MARKET STATS